Optimal control of acute cisplatin-induced emesis

被引:24
作者
Verweij, J
deWit, R
deMulder, PHM
机构
[1] UNIV HOSP,ROTTERDAM,NETHERLANDS
[2] UNIV NIJMEGEN HOSP,DEPT INTERNAL MED,DIV MED ONCOL,NL-6500 HB NIJMEGEN,NETHERLANDS
关键词
chemotherapy-related emesis; 5-HT3; antagonists; antiemetics; cisplatin-induced emesis;
D O I
10.1159/000227642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A survey by Coates and co-workers in 1983 revealed that patients ranked nausea and vomiting as the most distressing side effects of chemotherapy. In the last decade the use of high-dose metoclopramide and, especially, the introduction of the 5-HT3 receptor antagonists, have been major leaps forward in the control of chemotherapy-induced emesis. Nevertheless, since patients still consider nausea and vomiting to be the most distressing side effect of their chemotherapy there is clearly a need for further improvements. Acute emesis, which is the topic of this review, can now be controlled in the majority of patients during their first course of chemotherapy. Future focus should be on better control of emesis during subsequent courses of chemotherapy as well as on better control of delayed emesis.
引用
收藏
页码:56 / 64
页数:9
相关论文
共 86 条
[1]   SETRON - ARE 5-HT(3) RECEPTOR ANTAGONISTS DIFFERENT [J].
AAPRO, MS .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (12) :1655-1655
[2]  
AAPRO MS, 1991, RECENT RESULTS CANC, P91
[3]  
AGOSTINUCCI WA, 1986, CLIN PHARMACY, V5, P150
[4]   DEXAMETHASONE AND HIGH-DOSE METOCLOPRAMIDE - EFFICACY IN CONTROLLING CISPLATIN INDUCED NAUSEA AND VOMITING [J].
ALLAN, SG ;
CORNBLEET, MA ;
WARRINGTON, PS ;
GOLLAND, IM ;
LEONARD, RCF ;
SMYTH, JF .
BRITISH MEDICAL JOURNAL, 1984, 289 (6449) :878-879
[5]  
ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
[6]  
ANTHONY L, 1985, J CLIN ONCOL, V4, P98
[7]  
BASURTO C, 1988, CANC INVEST, P475
[8]   STRATIFIED, RANDOMIZED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON ADMINISTERED AS A MULTIPLE-DOSE REGIMEN VERSUS 2 SINGLE-DOSE REGIMENS IN THE PREVENTION OF CISPLATIN-INDUCED NAUSEA AND VOMITING [J].
BECK, TM ;
HESKETH, PJ ;
MADAJEWICZ, S ;
NAVARI, RM ;
PENDERGRASS, K ;
LESTER, EP ;
KISH, JA ;
MURPHY, WK ;
HAINSWORTH, JD ;
GANDARA, DR ;
BRICKER, LJ ;
KELLER, AM ;
MORTIMER, J ;
GALVIN, DV ;
HOUSE, KW ;
BRYSON, JC .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (12) :1969-1975
[9]   EFFICACY OF ORAL ONDANSETRON IN THE PREVENTION OF EMESIS IN OUTPATIENTS RECEIVING CYCLOPHOSPHAMIDE-BASED CHEMOTHERAPY [J].
BECK, TM ;
CIOCIOLA, AA ;
JONES, SE ;
HARVEY, WH ;
TCHEKMEDYIAN, NS ;
CHANG, A ;
GALVIN, D ;
HART, NE .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (06) :407-413
[10]   LORAZEPAM - A RANDOMIZED, DOUBLE-BLIND, CROSSOVER STUDY OF A NEW ANTIEMETIC IN PATIENTS RECEIVING CYTO-TOXIC CHEMOTHERAPY AND PROCHLORPERAZINE [J].
BISHOP, JF ;
OLVER, IN ;
WOLF, MM ;
MATTHEWS, JP ;
LONG, M ;
BINGHAM, J ;
HILLCOAT, BL ;
COOPER, IA .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (06) :691-695